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Abstract
Purpose—Paired primary breast cancers and metachronous metastases after adjuvant treatment 
are reported to differ in their clonal composition and genetic alterations, but it is unclear whether 
these differences stem from the selective pressures of the metastatic process, the systemic 
therapies or both. We sought to define the repertoire of genetic alterations in breast cancer patients 
with de novo metastatic disease who had not received local or systemic therapy.
Experimental Design—Up to two anatomically distinct core biopsies of primary breast cancers 
and synchronous distant metastases from nine patients who presented with metastatic disease were 
subjected to high-depth whole-exome sequencing. Mutations, copy number alterations and their 
cancer cell fractions, and mutation signatures were defined using state-of-the-art bioinformatics 
methods. All mutations identified were validated with orthogonal methods.
Results—Genomic differences were observed between primary and metastatic deposits, with a 
median of 60% (range 6%–95%) of shared somatic mutations. Whilst mutations in known driver 
genes including TP53, PIK3CA and GATA3 were preferentially clonal in both sites, primary 
breast cancers and their synchronous metastases displayed spatial intra-tumor heterogeneity. 
Likely pathogenic mutations affecting epithelial-to-mesenchymal transition-related genes, 
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including SMAD4, TCF7L2 and TCF4 (ITF2), were found to be restricted to or enriched in the 
metastatic lesions. Mutational signatures of trunk mutations differed from those of mutations 
enriched in the primary tumor or the metastasis in six cases.
Conclusion—Synchronous primary breast cancers and metastases differ in their repertoire of 
somatic genetic alterations even in the absence of systemic therapy. Mutational signature shifts 
might contribute to spatial intra-tumor genetic heterogeneity.
Keywords
Massively parallel sequencing; metastatic breast cancer; somatic mutations; epithelial-
mesenchymal transition
INTRODUCTION
Although metastatic breast cancer remains incurable, the survival of patients with advanced 
disease has shown significant but incremental increases over the last three decades (1). 
Metastatic dissemination is a complex process and numerous molecular mechanisms have 
been described, including models where metastatic potential is an intrinsic characteristic of 
all cancer cells and the emergence of metastasis is a stochastic event (2), whereas others 
suggested that only subpopulations of cancer cells would be able to colonize other organs 
(3).
Breast cancers display intra-tumor genetic heterogeneity that vary between cases and may 
follow spatial patterns (4–7). Moreover, primary and metastatic lesions exhibit phenotypic 
differences, including changes in estrogen receptor (ER) and HER2 status in 7%–25% of 
cases (8, 9). Whole-genome analyses in pairs of breast cancers and metachronous metastases 
after adjuvant treatment revealed genetic differences in their clonal composition, mutational 
frequencies and structural alterations, suggesting that metastatic disease may emerge from a 
subclone rather than the dominant clone of the primary tumor (4). Furthermore, analyses of 
a primary breast cancer and its metastatic lesions revealed that resistance to a PI3K-alpha 
inhibitor was a convergent phenotype, with resistant metastatic deposits harboring different 
PTEN mutations (10). By contrast, targeted massively parallel sequencing analyses of 
hotspot mutations or cancer genes demonstrated limited differences between primary tumors 
and their respective metastases (11–13), and suggested that genotyping the primary tumor 
may be acceptable to guide systemic treatment if the metastatic sample is not obtainable 
(12). Crucially, whether the differences are due to the selective pressures imposed by the 
metastatic process itself, the systemic therapies or both, remains unclear.
Approximately 6%–10% of breast cancers present with metastatic disease at diagnosis (1). 
Analysis of primary and metastatic lesions from these patients provides a unique opportunity 
to investigate potential differences in their repertoire of somatic genetic alterations without 
the effects of the selective pressures imposed by systemic therapies. This is of clinical 
importance, given that if the driver genetic alterations present in a given primary tumor are 
distinct from those of its metastatic deposit even without systemic therapy, it would impact 
on how precision medicine can be implemented and on the selection of samples for genetic 
analyses (14).
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In this study, we subjected up to two anatomically distinct biopsies of primary breast cancers 
and up to two anatomically distinct biopsies of their synchronous metastatic deposits from 
patients who presented with de novo metastatic disease and had not received any local or 
systemic therapy to gene copy number analysis and high-depth whole-exome sequencing 
(WES). All somatic mutations identified by WES were subsequently validated using 
orthogonal methods. Our aims were to determine the differences in the repertoires of 
somatic mutations, copy number alterations (CNAs) and mutational signatures (15) between 
primary breast cancers and their metastases, and to define whether clonal compositions 
would change from the primary tumor to its metastatic deposit in the absence of any 
systemic therapy.
MATERIALS AND METHODS
Tissue sample collection
Diagnostic biopsies of primary tumors and synchronous distant metastases were collected 
from nine patients with stage IV breast cancer at presentation, before any systemic 
treatment, as part of the routine clinical diagnostic workup. These biopsies were routinely 
processed, formalin-fixed and paraffin-embedded (FFPE). Second anatomically distinct 
biopsies from primary tumors and metastases from each patient were collected and flash-
frozen as part of the prospective study Changes in Phenotype and Genotype of Breast 
Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE, 
NCT01956552) at Institut Curie (Paris, France; Supplementary Table S1). All patients gave 
informed written consent, allowing the collection, storage and genomic analysis of the 
biopsies. Peripheral blood leukocytes collection for germline DNA sequencing was 
authorized by a further informed written consent. This study was approved by the 
Institutional Review Boards of the authors’ institutions.
Frozen biopsies from the primary tumor and synchronous metastasis were available for all 
cases. FFPE biopsies from both the primary and same distant metastatic lesions were also 
available for Cases 1, 5 and 7–9. For Case 4, a FFPE biopsy was only available from the 
primary tumor, whereas for Case 6, a FFPE biopsy was only available from the same 
metastasis. For Cases 2 and 3, no FFPE biopsies were available (Supplementary Table S2). 
Previous genomics analyses of case 5 were reported elsewhere (16) (Supplementary 
Methods).
Immunohistochemistry
Immunohistochemistry using antibodies against ER, progesterone receptor (PR) and HER2 
was performed as previously described (5) and evaluated according to the American Society 
of Clinical Oncology/College of American Pathologists guidelines (17, 18) (Supplementary 
Methods).
Microdissection and DNA extraction
Fifteen representative eight-μm-thick histologic sections of the frozen and FFPE biopsies of 
the primary tumors and metastases were subjected to microdissection and DNA extraction as 
previously described (19) (Supplementary Methods).
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WES of frozen biopsies
DNA extracted from frozen biopsies of the primary tumors, metastases and germline were 
subjected to exome capture using SureSelect Human All Exon v4 (Agilent) and to massively 
parallel sequencing on an Illumina HiSeq 2000 following validated protocols (19) 
(Supplementary Table S2, Supplementary Methods). WES data have been deposited in the 
Sequence Read Archive (SRP055001).
WES data processing was performed as previously described (19). Somatic single nucleotide 
variants (SNVs) were identified using MuTect (v1.0) (20) and somatic small insertions and 
deletions (indels) were identified using GATK (v2.7.4) (21) and the micro-assembly-based 
Scalpel (v0.1.1) (22) (Supplementary Methods).
Validation of mutations in frozen samples and discovery in FFPE samples
Orthogonal validation of mutations found by WES in the frozen samples and mutation 
discovery in the FFPE samples were performed by either targeted capture sequencing using 
a customized bait set (EzCap, Nimblegen, Roche) on an Illumina HiSeq 2000 or amplicon 
sequencing using a custom AmpliSeq panel on an Ion Torrent Personal Genome Machine 
(Supplementary Tables S2, Supplementary Methods).
Gene copy number profiling
FACETS (23) was used to define CNAs for samples subjected to WES. DNA extracted from 
microdissected FFPE and selected frozen biopsies were subjected to copy number profiling 
using the OncoScan v3 molecular inversion probe array (Affymetrix) following 
manufacturer’s instructions (16) (Supplementary Table S2, Supplementary Methods).
Segmented Log2 ratios from FACETS (WES) and Nexus Express for OncoScan (OncoScan) 
were used as input for ABSOLUTE (v1.0.6) (24) to determine integer copy number and 
cancer cell fractions (CCFs) of CNAs. CNAs were defined using the modal copy number 
from ABSOLUTE (Supplementary Methods). Regions of loss of heterozygosity (LOH) were 
defined using FACETS (WES) and Nexus Express for OncoScan (OncoScan). For six 
sample with both OncoScan and FACETS results, a substantial to perfect agreement for the 
CNA profiles was observed (median Cohen’s weighted kappa 0.85, range 0.76–0.88; 
Supplementary Fig. S1A, Supplementary Table S2).
Identification of likely pathogenic mutations
A combination of MutationTaster (25), CHASM (breast) (26) and FATHMM (27) was used 
to define the potential functional effect of each missense SNV. In-frame indels defined as 
“neutral” by MutationTaster (25) and PROVEAN (28) were considered likely passengers. 
The remaining in-frame indels, as well as frameshift, splice-site and nonsense mutations 
were considered likely pathogenic if they were targeted by loss of the wild-type allele (i.e. 
LOH) or affected haploinsufficient genes (29). SNVs affecting hotspot residues (30) were 
considered likely pathogenic. Mutations affecting cancer genes (31–33) were annotated. 
Mutations that were neither likely pathogenic nor likely passenger were considered of 
indeterminate pathogenicity (Supplementary Methods).
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Classification of trunk and branch mutations, and mutations enriched in the primary or 
metastatic lesion
The CCF of each validated mutation was inferred using ABSOLUTE (24) (Supplementary 
Methods). A mutation was considered ‘trunk’ if it was clonal in all available biopsies in any 
given patient. We defined mutations ‘specific to the metastatic lesion’ as those present in at 
least one biopsy of the metastasis but absent from all biopsies of the primary tumor from the 
same patient and defined mutations ‘enriched in the metastatic lesion’ as those associated 
with an increase in CCF by at least 20% in the metastasis compared to the primary tumor, 
and vice versa for mutations ‘specific to the primary tumor’ and ‘enriched in the primary 
tumor’.
Analysis of pathways associated with the metastatic process
To identify pathways that may be associated with the metastatic process, we analyzed the 
genes affected by likely pathogenic mutations specific to, enriched in the metastatic lesion 
(see above) and those associated with LOH in at least one biopsy of the metastasis and not 
associated with LOH in any biopsy of the matched primary tumor using Ingenuity Pathway 
Analysis (http://www.ingenuity.com) and g:Profiler (34) (Supplementary Methods).
Mutational signatures
Mutational signatures were defined as previously described (35), based on the Pearson’s 
correlation coefficient to the 12 breast cancer-associated mutational signatures (15, 36) 
(Supplementary Methods).
Phylogenetic tree construction
Maximum parsimony trees were built based on the repertoire of somatic mutations, gene 
amplifications and homozygous deletions as previously described (37) (Supplementary 
Methods).
Statistical analysis
All statistical analyses were performed in R v3.1.2. Comparisons of continuous and 
categorical variables were performed using Mann-Whitney U and Fisher’s exact tests, 
respectively. Associations were performed using the Spearman’s rank correlation tests. 
Agreement of CNAs was assessed using Cohen’s weighted kappa statistic. All statistical 
tests were two-tailed and P<0.05 was considered statistically significant.
RESULTS
Temporal and spatial genetic heterogeneity in primary breast cancers and synchronous 
metastatic deposits
Nine treatment-naïve breast cancer patients with stage IV metastatic disease at presentation 
from the prospective ESOPE study (NCT01956552) were included in this study 
(Supplementary Table S1). Cases 1–8 were invasive ductal carcinomas of no special type 
and Case 9 a metaplastic breast carcinoma. Five patients had metastases in multiple 
anatomical sites and four patients had a single metastasis (Supplementary Table S1). Across 
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all patients, liver (n=6) and bone (n=5) were the most common metastatic sites. Breast 
cancers of all clinical ER/HER2 subtypes were included and ER/HER2 status was 
concordant in primary tumors and their respective metastases in all patients tested. None of 
the patients received local or systemic therapy prior to the synchronous collection of 
diagnostic needle biopsies from the primary and metastatic deposits.
We first sought to determine whether the repertoire of somatic genetic alterations in biopsies 
of primary tumors and their respective metastases in treatment-naïve patients would differ. 
DNA extracted from two frozen biopsies, one from the primary tumor and one from a distant 
metastatic lesion (liver, n=5; bone, n=2; skin, n=1, contralateral axillary lymph node, n=1) 
from these nine patients was subjected to WES to median depths of 202× (range 189x–229x) 
in primary tumors, 207× (range 124x–277x) in metastases and 208× (range 58x–267x) in 
matched normal counterparts (Fig. 1A, Supplementary Table S2). Additionally, to define the 
spatial heterogeneity within the primary and metastatic lesions, we obtained a second, 
independent FFPE biopsy from the primary tumor of six cases (Cases 1, 4, 5, 7–9), and an 
independent FFPE biopsy from the same metastatic lesion in six cases (Cases 1, 5–9, Fig. 
1A, Supplementary Table S2). We subjected the DNA obtained from the FFPE biopsies of 
these seven patients to a combination of target capture sequencing and/or amplicon re-
sequencing to assess the presence of the somatic mutations found in the WES analysis of 
either or both frozen biopsies of the respective patients. WES analysis of the frozen biopsies 
of the primary and the metastatic deposits revealed the presence of 1,041 and 1,115 somatic 
mutations, all of which were subjected to validation using either targeted sequencing or 
amplicon re-sequencing and 889 (85%) and 1,049 (94%) of the mutations of the primary 
tumors and the metastatic deposits, respectively, were validated (Supplementary Methods, 
Supplementary Tables S2–S3) and were included in subsequent analyses.
Restricting the analyses to the two frozen biopsies of each patient revealed significantly 
more somatic mutations in the metastatic lesions (median 110, range 31–239) than in the 
primary tumors (median 78, range 31–204, P=0.0209, paired Mann-Whitney U test, Fig. 
1A). When we considered the targeted sequencing of the additional second biopsies of the 
six primary tumors and the six metastatic lesions, we identified a median of one (range 0–
23) and 0 (range 0–2) additional mutations in the primary and metastatic lesions, 
respectively (Fig. 1A).
Akin to a clinical scenario, where single diagnostic biopsies are employed for sequencing 
analysis, we compared the repertoire of mutations detected in the single frozen biopsies of 
the primary and metastatic lesions from each patient, which revealed a median of 60% 
(range 6%–95%) of somatic mutations in common (Fig. 1B). Importantly, however, 
substantial heterogeneity was observed, with a median of 12% (0%–44%) and a median of 
24% (3%–52%) of mutations restricted to the primary and the metastatic lesions, 
respectively (Fig. 1B).
We next sought to define if including an additional anatomically distinct biopsy of the 
primary tumor and of its metastatic lesion would mitigate the apparent heterogeneity 
observed between the lesions. In the five cases with two biopsies of both the primary and 
metastatic lesions, if a single biopsy of the primary tumor and the metastasis were 
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employed, a median of 22% (3%–50%) of mutations would be restricted to the metastatic 
lesion. Including the additional anatomically distinct biopsies of the two lesions slightly 
reduced this proportion to 21% (3%–47%, Fig. 1B), suggesting that heterogeneity between 
primary tumor and metastases can be only marginally mitigated by the inclusion of second 
anatomically distinct biopsies.
Distinct repertoire of genetic alterations in primary breast cancers and synchronous 
metastatic deposits
Previous studies based on the analysis of hotspot mutations or cancer genes have suggested 
limited genetic differences between primary tumors and their metastases (11–13). These 
observations suggest that the genetic heterogeneity observed between primary tumors and 
their synchronous metastases would constitute genetic drift (38) and therefore the 
heterogeneity would preferentially affect passenger alterations (6). Since having second 
anatomically distinct biopsies only marginally mitigated the mutational differences, we 
focused on the frozen biopsies of the synchronous primary breast cancer and the metastases 
to compare their repertoires of somatic mutations. We identified a median of seven (range 3–
21) likely pathogenic mutations per case (primary and/or metastasis), including a median of 
three (range 0–5) likely pathogenic mutations in cancer genes (31–33) (Fig. 2A, 
Supplementary Fig. S2A). Six cases each harbored one hotspot mutation, all of them shared 
between primary and metastasis, namely PIK3CA H1047R (Cases 2 and 4), TP53 R248W/
R282W/R196* (Cases 3, 5 and 7, respectively) and NFE2L2 R34G (Case 9, Supplementary 
Table S3).
Consistent with the observations that driver mutations tend to be clonal (i.e. present in 
virtually 100% of tumor cells) (4, 37), 24/28 (86%) of the likely pathogenic mutations 
affecting cancer genes were found in the frozen biopsies of both the primary and their 
synchronous metastases and 22/28 (79%) were clonal in both (Fig. 2B). This is in agreement 
with previous analyses restricted to hotspot mutations and/or mutations affecting known 
cancer genes (11–13). Indeed, all TP53 (n=7), PIK3CA (n=2) and GATA3 (n=1) mutations 
were clonal in both biopsies (Fig. 2A). We also identified clonal likely pathogenic mutations 
affecting the cancer genes RAD21, BRCA2, ERBB3, RB1 and ATR in single primary-
metastasis pairs. In the one case without likely pathogenic mutations affecting cancer genes 
(Case 1), we identified clonal likely pathogenic mutations affecting RHOB and FLT1, as 
well as focal amplifications in 8q24.21 (encompassing MYC) and 17q12 (ERBB2) in both 
lesions (Fig. 2A, Supplementary Fig. S1B, Supplementary Table S3).
Despite limited heterogeneity in the repertoire of hotspot mutations or mutations affecting 
known cancer genes between primary tumors and their respective metastases, in four cases, 
likely pathogenic mutations affecting cancer genes were found to be restricted to the 
metastatic lesions, namely, TCF7L2 S122* in Case 5, SMAD4 D355G and PSIP1 I412fs, 
both associated with LOH, in Case 7, and FLT4 A835T in Case 8 (Fig. 2A). Notably, these 
four mutations were not identified in the primary tumors even with a second, anatomically 
distinct biopsy (Supplementary Fig. S2A).
In agreement with the hypothesis that heterogeneity would preferentially affect passenger 
alterations (6), mutations of indeterminate pathogenicity, likely passenger and synonymous 
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mutations were less frequently present in both lesions than likely pathogenic mutations in 
cancer genes (53%, 56% and 57% vs 86%, and P=0.0007, P=0.0021 and P=0.0023, 
respectively, Fisher’s exact tests, Fig. 2B). Likely pathogenic mutations (affecting any gene) 
were also more frequently concurrently present or clonal in the frozen biopsies of both 
lesions than indeterminate/likely passenger/synonymous mutations (75% vs 55% and 66% 
vs 43%, P=0.0002 and P<0.0001, respectively, Fisher’s exact tests, Fig. 2B). Similar results 
were obtained when the additional FFPE biopsies of the primary tumor and metastases were 
included, with likely pathogenic mutations (affecting any gene) more frequently present or 
clonal in all available biopsies compared to indeterminate/likely passenger/synonymous 
mutations (73% vs 53% and 49% vs 37%, P=0.0003 and P=0.0299, respectively, Fisher’s 
exact tests, Supplementary Fig. S2B).
Copy number analysis revealed that 62% (29/47) of focal amplifications and homozygous 
deletions were found in both lesions, including amplification affecting MYC (Cases 1, 5 and 
7), ERBB2 (Cases 1, 2, 3, 6 and 7), EGFR (Case 2), AKT1 (Case 8), FGFR1 (Case 7) and 
MAP2K3 (Cases 3 and 7) (Fig. 3A, Supplementary Fig. S1B, Supplementary Table S3). 
Important differences between the primary and the metastasis were also observed; in Case 7, 
53% (10/19) and 11% (2/19) of amplifications were restricted to the primary and the 
metastatic lesions, respectively, and in Case 9, one of two amplifications was restricted to 
the metastasis (Fig. 3B). Notably, five homozygous deletions were found exclusively in the 
metastases of Cases 5, 7 and 9 (Fig. 3B and Supplementary Table S3), including 17p12 
(encompassing MAP2K4) and 19q13.42 (KIR3DL3) in Case 5, 17p13.1 (TNFSF12 and 
SENP3) and 20p13 (SOX12) in Case 7 and 9q34.3 (MAMDC4) in Case 9, none of which 
could be detected in the second biopsies of the primary tumors of the respective patients.
Taken together, these results suggest that although the majority of likely pathogenic 
mutations affecting any (75%) or cancer genes (86%, including all hotspot mutations), as 
well as 62% of amplifications and homozygous deletions, were present in the frozen 
biopsies of primary tumors and their synchronous metastases in treatment-naïve breast 
cancer patients, potential driver mutations (14% of the likely pathogenic mutations affecting 
cancer genes) were restricted to the metastatic deposit and absent in up to two biopsies of 
the primary tumor. These results demonstrate that heterogeneity between primary breast 
cancers and their synchronous metastases in the absence of systemic therapy preferentially, 
but not exclusively, affected passenger genetic alterations.
Likely pathogenic mutations affecting epithelial-to-mesenchymal transition (EMT)-related 
genes are enriched for in metastases
Although the heterogeneity between primary tumors and their metastases preferentially 
affected passenger genetic alterations, we found likely pathogenic mutations in cancer genes 
FLT4, PSIP1, SMAD4 and TCF7L2 restricted to the metastases. We therefore sought to 
investigate whether the metastatic process was associated with specific biological pathways. 
Pathway analysis on 22 genes affected by likely pathogenic mutations specific to or enriched 
in (i.e. increase in CCF by at least 20% compared to the primary lesions (frozen and FFPE 
whenever available)) or associated with LOH in the metastatic lesions but not the primary 
lesions (Fig. 4A) revealed an enrichment in genes associated with the regulation of EMT 
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using Ingenuity Pathway Analysis (P<0.0001, Fig. 4B, Supplementary Table S4). These 
EMT-associated mutations were identified in four cases, with JAK3 E1033D mutation 
associated with LOH in the metastasis but not the primary tumor in Case 4, SMAD4 D355G 
mutation associated with LOH in Case 7, TCF7L2 (Transcription factor 7-like 2, also called 
TCF4 or T-cell factor 4, chr10q25.3) S122* mutation in Case 5, and TCF4 (Transcriptional 
factor 4, also called ITF2 or immunoglobulin transcription factor 2, chr18q21.1) splice site 
c.379–1G>C mutation associated with LOH in Case 9. We further refined the analysis to 
genes rarely mutated (<1%) in primary breast cancers (39) and of the remaining 21 genes, 
the enrichment remained significant (P<0.0001). Interrogating the KEGG and Reactome 
pathways using g:Profiler (34) showed that these 22 and 21 genes were significantly 
enriched in the KEGG adherens junction pathway (P=0.0001 and P=0.0141, respectively, 
Supplementary Table S4).
Evolutionary dynamics of somatic mutations and CNAs
Single cell sequencing studies suggested that whilst mutations are acquired gradually, CNAs 
develop in punctuated bursts of evolution (6, 7). We sought to explore whether somatic 
mutations and CNAs may display distinct evolutionary patterns using the integrated 
ABSOLUTE framework that simultaneously quantifies the CCFs of somatic mutations and 
CNAs (24). A median of 24% (range 4%–42%) and 16% (range 5%–28%) of the mutations 
in the frozen biopsies of the primary and the metastatic lesions, respectively, were subclonal 
(Fig. 5). By contrast, there was little intra-tumor CNA heterogeneity, with a median of 100% 
(range 89%–100%) and 97% (75%–100%) of CNAs (excluding amplifications, see 
Supplementary Methods) found to be clonal in the primary and the metastatic lesions, 
respectively. There was no difference or association between the proportion of subclonal 
mutations or of subclonal CNAs within primary-metastasis pairs (all P>0.05, paired Mann-
Whitney U and Spearman’s correlation tests). Moreover, the proportion of subclonal 
mutations and CNAs did not show correlation in either the primary or the metastatic lesions 
(both P>0.05, Spearman’s correlation tests), suggesting that mutations and CNAs likely 
evolved independently. Crucially, we observed in all cases that the CCFs of somatic 
mutations formed a continuous spectrum whereas the vast majority of CNAs were found in 
all cancer cells. An analysis of the proportion of subclonal mutations and CNAs, alone or 
together, revealed no difference between the primary tumors stratified by ER or HER2 
status, triple-negative phenotype, grade (2 vs 3), number of metastatic sites (1 vs >1), the 
presence of liver metastasis and the presence of bone metastasis, and between the metastatic 
lesions stratified by ER or HER2 status, triple-negative phenotype, and metastatic site 
biopsied (liver vs bone, all P>0.05, Mann-Whitney U tests). We further found no correlation 
between heterogeneity within the primary tumor and its volume or the volume of total 
metastases (both P>0.05, Spearman’s correlation tests). Taken together, our results suggest 
that the evolutionary trajectories of somatic mutations and CNAs are distinct, with mutations 
accumulating in a gradualistic manner, whereas CNAs likely occurred in punctuated bursts 
of evolution.
Shifts in mutational signatures
We hypothesized that, akin to the switch from the smoking-associated mutational signature 
to that of APOBEC cytidine deaminase activity in lung cancers evolution (40), the 
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mutational processes that shaped breast cancer genomes may evolve over time. We therefore 
compared the mutational signatures that underpin i) trunk mutations, ii) mutations specific to 
or enriched in the primary tumors and iii) mutations specific to or enriched in the metastatic 
lesions to 12 mutational signatures previously reported in breast cancer (36) for all cases 
except Case 5, for which there were not sufficient non-trunk mutations to perform this 
analysis. In six cases, our analysis suggested shifts in the dominant mutational signatures 
during tumor evolution (Fig. 6A, Supplementary Fig. 3A). The trunk mutations displayed 
several different signatures, with signatures 1 (associated with aging), 2 and 13 (C>T 
transitions and C>G transversions, respectively, in the TpCpW context, associated with 
APOBEC cytidine deaminase activity) being the most frequent, suggesting that the 
biological processes driving trunk mutations may vary from patient to patient. Interestingly, 
we observed that mutational signatures were not constant throughout tumor evolution, with 
shifts in mutational signatures detected between trunk mutations and mutations specific to or 
enriched in the primary and/or metastatic lesions. Although no consistent pattern in the 
shifts between trunk and non-trunk mutations was detected, four of eight cases displayed a 
dominant signature 13 in the non-trunk mutations, with the APOBEC signature frequently 
found in both the mutations enriched in or specific to primary tumors (Cases 2, 4, 7 and 9) 
and the mutations enriched in or specific to the metastatic lesions (Cases 2, 4 and 9, Fig. 6B, 
Supplementary Fig. 3B). Notably, these four cases spanned the entire spectrum of clinical 
ER/HER2 phenotypes, suggesting the APOBEC signature is not restricted to specific 
subtypes of breast cancer.
DISCUSSION
As the biopsies for this study were de facto diagnostic core biopsies, our study addresses an 
important clinical question, namely whether sequencing analysis of primary tumors is 
representative of the metastatic deposits in the absence of systemic therapy. Consistent with 
previous studies (11, 12), we demonstrated that pathogenic mutations affecting known breast 
cancer genes were present in both the primary tumors and their respective metastases and 
that heterogeneity preferentially affected passenger alterations. Importantly, however, likely 
pathogenic mutations affecting the cancer genes SMAD4, PSIP1, TCF7L2 and FLT4 were 
found only in the synchronous metastases even with a second, anatomically distinct 
diagnostic biopsy of the respective primary tumors. In fact, the mutational differences 
observed between primary tumor and metastases were only marginally mitigated by 
including second, anatomically distinct diagnostic biopsies of the primary and of the 
metastatic lesions. Among the likely pathogenic mutations, only one (ASB15 R528H in 
Case 7) was ‘rescued’ by a second biopsy of the primary tumor. Thus, the information 
extracted from a second biopsy of the primary tumor might not be sufficient to overcome the 
challenges posed by intra-tumor genetic heterogeneity.
Previous sequencing studies of cancer-associated genes revealed that TP53, PTEN, KRAS 
and SMAD4 were among the genes most frequently affected by mutations restricted to the 
metastasis (11, 12, 41, 42). Although TP53, PTEN and KRAS mutations were not found to 
be restricted to or enriched in the metastases in this study, we have identified a likely 
pathogenic SMAD4 mutation associated with LOH, along with likely pathogenic mutations 
affecting other EMT-related genes, such as TCF7L2 and TCF4 (ITF2), restricted to or 
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enriched in the metastases. EMT, a phenomenon by which epithelial cells acquire invasive 
and migratory properties, has been shown to be key to the metastatic process (43). SMAD4 
loss has been implicated in the metastatic spread of breast cancer in preclinical models (44), 
and SMAD4 mutations restricted to metastases have been reported in three breast cancers 
(11, 12) and in two colorectal cancers with synchronous liver metastasis (42). TCF7L2 loss-
of-function mutations have been shown to activate Wnt pathway (45), which plays pivotal 
roles in EMT, and knock-down of TCF4 (ITF2) deregulates TGF-β signaling, EMT and 
apoptosis (46). Our analyses also resulted in the identification of metastasis-specific 
secondary LOH events associated with likely pathogenic mutations affecting JAK3 and 
FLT4. Alterations in both genes have previously been described as metastasis-specific, with 
a JAK3 mutation restricted to the liver metastasis of a colorectal cancer (42) and a FLT4 
mutation restricted to the liver metastasis of a breast cancer (47). We did not observe specific 
patterns in terms of the number of private mutations in the metastases, likely pathogenic 
mutations enriched in the metastases or mutational signature in the five liver metastases or 
the two bone metastases, or any significant associations between the number of mutations 
and histopathologic parameters, such as histologic grade, tubule formation, nuclear 
pleomorphism and mitotic index (Supplementary Table S1).
The mutational processes that shape cancer genomes leave imprints as mutational signatures, 
many of which are linked to specific biological phenomena (15, 36). In our study, we found 
evidence that somatic mutations are acquired in a gradualistic manner and, akin to lung 
cancer (40), mutational processes are not constant in breast cancers throughout tumor 
evolution, even in the absence of selective pressures imposed by systemic therapy. The 
evolution of mutational signatures was observed across all ER/HER2 clinical subtypes and 
did not follow a specific pattern, however the C>G APOBEC-associated signature 13, which 
is frequent in breast cancer (36), was found to be enriched in the non-trunk mutations and 
likely contributed to the genetic diversity of four of eight cancers studied. By contrast, and 
consistent with observations derived from single-cell sequencing analysis (6, 7), most CNAs 
were found to be present in all cancer cells, suggesting that these were acquired in 
punctuated bursts of evolution. Although the number of mutations for the analyses of 
mutational signatures was relatively small in some sets of mutations, our findings support 
the notion that the evolution of mutational signatures parallels that of the somatic mutations 
over time in several cases, and may suggest that, in breast cancer, the C>G APOBEC 
mutational process is linked to tumor evolution rather than early tumor development, 
consistent with the findings reported by Lefebvre et al (48), who observed that 
approximately 59% of the mutations found in hormone receptor-positive/HER2–negative 
metastatic tumors were consistent with signatures 2 and 13, whereas only 32% of the 
mutations detected in hormone receptor-positive/HER2–negative primary breast cancers 
displayed this pattern. Furthermore, the lack of correlation between the extent of subclonal 
mutations and CNAs supports the hypothesis that somatic mutations and CNAs evolve 
independently (6, 7).
Our study has important limitations. First, we studied patients with stage IV breast cancers, 
which account for a minority of breast cancers in the developed world (1), and it has been 
hypothesized that these breast cancers may have a different biology (3). Notably, three of the 
patients here had an apparent history of neglected breast cancer, but the findings from these 
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cases were consistent with those of the remaining patients. Second, none of the cases 
analyzed displayed a change in ER/HER2 status from the primary tumor to the metastatic 
lesion, as reported in a subset of cases (8, 9), and the genetic heterogeneity between paired 
primary and metastatic tumors with discrepant ER/HER2 status are likely to be more 
conspicuous. Third, targeted sequencing panels were performed in the DNA extracted from 
the FFPE biopsies; it is plausible that WES would reveal more profound intra-tumor 
heterogeneity. Fourth, although the presence of mutations restricted to the metastatic lesions 
does not prove that these mutations play a causative role in the development of metastasis 
and no genetic alteration was identified as a common denominator of breast cancer 
metastasis, our findings are consistent with the notion that the metastatic ability of cancer 
cells likely constitutes a convergent phenotype (49).
Here we report that primary breast cancers and their distant metastatic outgrowths differ in 
their repertoire of somatic genetic alterations in therapy-naïve patients. Our results suggest 
that mutational signature shifts may contribute to intra-tumor genetic heterogeneity and that 
metastatic spread in breast cancer is coupled to an enrichment of mutations in EMT-related 
genes. As most bona fide and currently actionable drivers of the disease are truncal, 
sequencing of the primary lesions alone even in therapy-naïve metastatic breast cancer 
patients may be clinically acceptable until additional alterations or specific pathways 
become actionable. In fact, therapeutic agents targeting the Wnt pathway, which plays 
pivotal roles in EMT, have entered clinical trials (50). WES of metastases from these 
patients may enable the discovery of new late drivers of breast cancer and of the metastatic 
process in the research setting. Given the distinct repertoire of genetic alterations in 
synchronous primary breast cancers and metastases in therapy-naïve patients, caution should 
be exercised with the use of agents targeted to mutations identified in a primary tumor to 
treat metastatic disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial support: The ESOPE (NCT01956552) study was funded by the INCa - French Ministry of Health 
(PHRC 2009 AOM 09 267). F.-C. Bidard was supported by a grant from the Nuovo-Soldati Foundation for Cancer 
Research and Institut Curie SiRIC (INCa-DGOS N° 4654). S. Piscuoglio is funded by Swiss National Science 
Foundation (Ambizione grant number PZ00P3_168165). J. S. Reis-Filho is funded in part by the Breast Cancer 
Research Foundation (BCRF). Research reported in this publication was supported in part by a Cancer Center 
Support Grant of the National Institutes of Health/National Cancer Institute (Grant No. P30CA008748). The 
content is solely the responsibility of the authors and does not necessarily represent the official views of the 
National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to 
publish, or preparation of the manuscript.
The authors would like to thank Odette Mariani for her assistance at the Institut Curie Tumor Biobank.
Abbreviations
CCF cancer cell fraction
CNA copy number alteration
Ng et al. Page 12
Clin Cancer Res. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
EMT epithelial-to-mesenchymal transition
ER estrogen receptor
FFPE formalin-fixed paraffin-embedded
Indel small insertion and deletion
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STATEMENT OF TRANSLATIONAL RELEVANCE
Despite the incremental increases in the survival of patients with metastatic disease over 
the past decades, metastatic breast cancer remains incurable. Analyses of primary breast 
cancers and their metastases after adjuvant treatment have revealed limited but important 
genetic differences. Whole-exome sequencing analysis of primary and metastatic breast 
cancers from therapy-naïve patients with stage IV disease, revealed that mutations 
affecting cancer genes were largely present and clonal in both primary tumors and their 
respective metastases. Importantly, however, genetic differences were observed between 
primary tumors and their metastases and were associated with shifts in mutational 
signatures and an enrichment for mutations affecting epithelial-to-mesenchymal 
transition (EMT)-related genes in the metastatic lesions. With the increasing number of 
actionable alterations, and of agents targeting components of the EMT pathway being 
tested in clinical trials, sequencing metastatic lesions in addition to primary tumors may 
help realize precision medicine in therapy-naïve metastatic breast cancer patients.
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Fig. 1. Spatial and temporal heterogeneity in primary and metastatic lesions in treatment-naïve 
synchronous metastatic breast cancer
(A) Barplots depict the number of somatic mutations identified in single frozen biopsies of 
the primary tumors and metastatic lesions, and for seven patients, the additional mutations 
identified by analyzing an additional FFPE biopsy of the corresponding tumor. Available 
biopsy samples are indicated by black dots below the barplots. (B) Venn diagrams illustrate 
the number of somatic mutations and the number of likely pathogenic mutations (in bold) 
present in each of the biopsies. Genes affected by likely pathogenic mutations are listed, 
with those affecting cancer genes (31–33) labeled in orange. PFr: frozen biopsy of primary; 
PFFPE: FFPE biopsy of primary; MFr: frozen biopsy of metastasis; MFFPE: FFPE biopsy of 
metastasis. FFPE, formalin-fixed paraffin-embedded.
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Fig. 2. Distinct repertoire of somatic genetic alterations in treatment-naïve primary breast 
cancers and synchronous metastatic deposits
(A) Heatmaps indicate the cancer cell fraction of somatic mutations as determined by 
ABSOLUTE (24) (blue, see color key) or their absence (grey) in each frozen biopsy. Likely 
pathogenic mutations are indicated by red dots and the affected genes are shown to the left 
of the heatmap. Likely pathogenic mutations affecting cancer genes (31–33) are further 
indicated by orange dots and gene names labeled in orange. Cases are grouped according to 
their ER/HER2 status. P: primary tumor; M: metastatic tumor. (B) Barplots of the 
distribution of mutations (top) present and (bottom) clonal in frozen biopsies of the paired 
primary tumors and the metastatic lesions, classified as likely pathogenic (cancer genes), 
likely pathogenic (other genes), of indeterminate pathogenicity, likely passenger and 
synonymous mutations from all patients. Comparisons between the groups of mutations of 
different pathogenicity were performed using Fisher’s exact tests. *: p < 0.01, **: p < 0.001, 
ns: not significant.
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Fig. 3. Copy number alterations in treatment-naïve primary and synchronous metastatic lesions
(A) Heatmap illustrating the copy number alterations, where samples are presented on the X 
axis (columns) and chromosomal positions are presented on the Y axis (rows). ER/HER2 
status of the tumor samples and sample types are indicated in the phenobar. Dark blue: 
amplification, light blue: copy number gain; white: neutral; light red: copy number loss; dark 
red: homozygous deletion. (B) Genome plots of the primary tumor and the distant metastatic 
lesion for cases 5, 7 and 9. In the genome plots, segmented Log2 ratios (y-axis) were plotted 
according to their genomic positions (x-axis). Alternating blue and grey demarcate the 
chromosomes. The amplifications and homozygous deletions restricted to the primary 
tumors or the distant metastatic lesions are highlighted with red and purple arrows, 
respectively.
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Fig. 4. Likely pathogenic mutations enriched in the metastases affect epithelial-mesenchymal 
transition-related genes
(A) Heatmaps indicate the cancer cell fractions of the somatic mutations as defined by 
ABSOLUTE (24) (blue boxes, see color key) or their absence (grey) in each biopsy. Red 
dots indicate likely pathogenic mutations and those affecting cancer genes (31–33) are 
indicated by orange dots. Genes affected by likely pathogenic mutations are labeled and 
those affected by likely pathogenic mutations specific to or enriched in the metastatic 
lesions, or were associated with the loss of the wild-type allele in the metastatic lesions but 
not the primary tumors labeled in blue. Phylogenetic trees depicting the evolution of the 
biopsies were constructed using the maximum parsimony method. The colored branches 
represent each of the subclones identified, and selected somatic genetic alterations that 
define a given clone are illustrated along the branches. The length of the branches is 
representative of the number of somatic mutations and copy number alterations 
(amplifications and homozygous deletions) that distinguishes a given clone from its 
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ancestral clone. PFr: frozen biopsy of primary; PFFPE: FFPE biopsy of primary; MFr: frozen 
biopsy of metastasis; MFFPE: FFPE biopsy of metastasis. (B) Venn diagram illustrates an 
enrichment of genes involved in EMT amongst the likely pathogenic mutations specific to, 
enriched in the distant metastasis or associated with the loss of the wild-type allele in the 
distant metastasis in the nine patients using Ingenuity Pathway Analysis. EMT, epithelial-
mesenchymal transition.
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Fig. 5. Evolutionary dynamics of somatic mutations and copy number alterations
Barplots illustrate the cancer cell fractions of the somatic mutations (red and light blue bars) 
and of the copy number alterations (grey bars, excluding amplifications, see Supplementary 
Methods). Cancer cell fractions of the somatic mutations and the copy number alterations 
are sorted in increasing order. Bars for somatic mutations are color-coded based on the 
pathogenicity according to the color key.
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Fig. 6. Evolution of mutational signatures in treatment-naïve patients with de novo synchronous 
metastatic breast cancer
(A) Heatmaps depicting the mutational signatures that shaped the genomes (15, 36) of the 
tumor samples analyzed, separately as trunk mutations (yellow), mutations enriched in the 
primary tumor (green) and mutations enriched in the metastatic lesion (pink). The similarity 
of each mutational signature to the breast cancer-associated signatures (36) is indicated in 
blue according to the color key. (B) Barplots illustrating the mutational signatures of the 
mutations enriched in the primary tumor and the metastatic lesion of Cases 2, 4, 7 and 9. In 
each panel, the colored barplot illustrates each mutational signature according to the 96 
substitution classification defined by the substitution classes (C>A, C>G, C>T, T>A, T>C 
and T>G bins) and the 5′ and 3′ sequence context, normalized using the observed 
trinucleotide frequency in the human exome to that in the human genome. The bars are 
ordered first by mutation class (C>A/G>T, C>G/G>C, C>T/G>A, T>A/A>T, T>C/A>G, 
T>G/A >C), then by the 5′ flanking base (A, C, G, T) and then by the 3′ flanking base (A, 
C, G, T). *: >20%.
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